Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Lilly

Zyprexa patent expirations impact results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly

1Q Revenues: $5.6 billion (-4%)

1Q Earnings: $1.0 billion (-4%)

Comments: Decline in revenues was driven by Zyprexa patent expirations, partially offset by Cymbalta, Forteo, Humalog, and Effient product growth, as well as a 41% revenue growth in China. Cymbalta sales were $1.1 billion, up 23%. Effient sales were $115.8 million, up 106%. Forteo sales were $271.3 million, up 26%. Humalog sales increased 12% to $590.3 million. Animal health products were $490.7 million, up 33%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters